Status:
COMPLETED
Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Conditions:
Healthy Volunteer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the safety, pharmacokinetics, and pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy Japanese non-elderly and elderly par...
Eligibility Criteria
Inclusion
- Body mass index (BMI) ≥18.5 and \<25.0 kg/m\^2 and body weight is more than 40.0 kg at screening inspection
- Other protocol defined inclusion criteria could apply
Exclusion
- History of clinically relevant disease of any organ system that may interfere with the objectives of the study or provide a risk to the health of the participant
- History of drug and food allergy
- Other protocol defined exclusion criteria could apply
Key Trial Info
Start Date :
September 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2019
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04087707
Start Date
September 17 2019
End Date
November 30 2019
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sumida Hospital
Sumida-ku, Tokyo, Japan, 130-0004